David Loison is an accomplished executive with extensive experience in finance and management across various industries, including biotech and pharmaceuticals. They served as Chief Financial Officer at LFB from 2015 to 2021 and as Chief Executive Officer at Jalon Therapeutics from 2022 to 2024, where they managed the development of innovative cancer therapies and secured funding. Currently, Loison holds the position of Interim Chief Financial Officer at KONE, overseeing operations in France, Belgium, and Luxembourg. They earned a Master’s degree from Sciences Po, further solidifying their expertise in strategic and financial management.
This person is not in the org chart
This person is not in any teams
This person is not in any offices